Roivant Sciences Ltd.
ROIV
$11.31
-$0.05-0.44%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
1/28/2025
-
MarketBeat
7/30/2025
-
Ticker Report
7/30/2025
-
MarketBeat
7/30/2025
-
MarketBeat
7/29/2025
-
Tickeron - Stocks
7/28/2025
-
Globe Newswire
7/28/2025
-
Ticker Report
7/25/2025
-
GuruFocus
7/25/2025
-
The Fly
7/25/2025
-
MarketBeat
7/24/2025
-
ETF Channel
7/24/2025
-
MarketBeat
7/24/2025
-
MarketBeat
7/23/2025
-
Insider Monkey
Mutual of America Capital Management LLC Sells 142,139 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)
7/20/2025
-
MarketBeat
7/16/2025
-
MarketBeat
7/15/2025
-
MarketBeat
7/15/2025
-
Tickeron - Stocks
7/14/2025
-
The Online Investor
7/11/2025
-
Zacks Investment Research
7/10/2025
-
MarketBeat
7/10/2025
-
GuruFocus
7/10/2025
-
TipRanks Financial Blog
7/10/2025
-
The Fly
7/10/2025
-
TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, May 29, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
44 20 7400 3347
Address
50 Broadway
London, SW1H 0DB
London, SW1H 0DB
Country
Year Founded
Business Description
Sector
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates...
more